Skip to main content
Wouter Plattel

As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.

Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR
Published in: BMC Cancer
BACKGROUND: Primary central nervous system lymphoma (PCNSL) are rare mature B-cell lymphoproliferative diseases characterized by a high incidence of MYD88 L265P and CD79B Y196 hotspot mutations. Diagnosis of PCNSL can be challenging. The aim of the study was to analyze the detection rate of the MYD88 L265P and CD79B Y196 mutation in cell free DNA (cfDNA) in plasma of patients with PCNSL. METHODS: We analyzed by digital droplet PCR (ddPCR) to determine presence of the MYD88 L265P and CD79B Y196 hotspot mutations in cfDNA isolated from plasma of...
Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands
Published in: Haematologica
Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of mature T-cell neoplasms with an unfavorable prognosis; presentation with stage I(E) disease is uncommon. In clinical practice, an abbreviated chemotherapy treatment regimen combined with radiotherapy (combined modality treatment (CMT)) is commonly used, although evidence from clinical trials is lacking. The aim of this nationwide population-based cohort study is to describe first-line treatment and outcome of patients with stage I(E) PTCL. All newly diagnosed patients ≥ 18 years with stage I(E) anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL)...
Frederik O Meeuwes, Mirian Brink, Wouter Plattel, Marjolein W M Van der Poel, Marie José Kersten, Mariëlle Wondergem, Lara Böhmer, F J Sherida H Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M Jansen, Karen J Neelis, Anne P G Crijns, Laurien A Daniëls, Tjeerd J F Snijders, Joost S P Vermaat, Gerwin A Huls, Marcel Nijland
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma
Published in: ESMO Open
Background: The introduction of rituximab significantly improved the prognosis of diffuse large B-cell lymphoma (DLBCL), emphasizing the importance of evaluating the long-term consequences of exposure to radiotherapy, alkylating agents and anthracycline-containing (immuno)chemotherapy among DLBCL survivors.  Methods: Long-term risk of subsequent malignant neoplasms (SMNs) was examined in a multicenter cohort comprising 2373 5-year DLBCL survivors treated at ages 15-61 years in 1989-2012. Observed SMN numbers were compared with expected cancer incidence to estimate standardized incidence ratios (SIRs) and absolute excess risks (AERs/10 000 person-years). Treatment-specific risks were assessed using...
Y. M. Geurts, S. I.M. Neppelenbroek, B. M.P. Aleman, C. P.M. Janus, A. D.G. Krol, D. J. van Spronsen, W. J. Plattel, J. M. Roesink, K. M.S. Verschueren, J. M. Zijlstra, H. R. Koene, M. R. Nijziel, E. C. Schimmel, E. de Jongh, F. Ong, L. C.J. te Boome, R. S. van Rijn, L. H. Böhmer, B. D.P. Ta, H. P.J. VisserE. F.M. Posthuma, Y. M. Bilgin, K. Muller, D. van Kampen, C. So-Osman, J. S.P. Vermaat, R. J. de Weijer, M. J. Kersten, F. E. van Leeuwen, M. Schaapveld
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma
Published in: Journal of Clinical Oncology
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The primary analysis of the Early positron emission tomography (ePET) Response-Adapted Treatment in localized Hodgkin Lymphoma H10 Trial demonstrated that in ePET-negative patients, the risk of...
Massimo Federico, Catherine Fortpied, Yana Stepanishyna, Manuel Gotti, Richard Van Der Maazen, Caterina Cristinelli, Alessandro Re, Wouter Plattel, Julien Lazarovici, Francesco Merli, Lena Specht, Jean Marc Schiano De Colella, Martin Hutchings, Annibale Versari, Véronique Edeline, Aspasia Stamatoulas, Theodore Girinsky, Umberto Ricardi, Berthe Aleman, Bart MeulemansSanne Tonino, John Raemaekers, Marc André
A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma
Published in: Blood Advances
Despite high cure rates in classic Hodgkin lymphoma (cHL), relapses are observed. Whether relapsed cHL represents second primary lymphoma or an underlying T-cell lymphoma (TCL) mimicking cHL is under-investigated. To analyze the nature of cHL recurrences, in-depth clonality testing of immunoglobulin (IG) and T-cell receptor (TR) rearrangements was performed in paired cHL diagnosis and recurrences of 60 patients, supported by targeted mutation analysis of lymphoma-associated genes. Clonal IG rearrangements were detected by next-generation sequencing (NGS) in 69/120 (58%) diagnosis and recurrence samples. The clonal relationship could be established...
Diede Ag van Bladel, Wendy B C Stevens, Leonie I Kroeze, Ruben Al de Groen, Fleur A de Groot, Jessica Lm van der Last-Kempkes, Madeleine R Berendsen, Jos Rijntjes, Jeroen A C W Luijks, Irina Bonzheim, Ellen van der Spek, Wouter J Plattel, Johannes Pruijt, Susan Dpwm de Jonge-Peeters, Gerjo A Velders, Chantal Lensen, Esther R van Bladel, Birgit Federmann, Brigiet Hoevenaars, Agata PastorczakJutte van der Werff Ten Bosch, Joost S P Vermaat, Peet Nooijen, Konnie M Hebeda, Falko Fend, Arjan Diepstra, J Han Jm van Krieken, Patricia J T A Groenen, Michiel van den Brand, Blanca Scheijen